Articles

Sort by
Previous Page Page 1 of 59 Next Page
  1. Review

    The immune system in cancer metastasis: friend or foe?

    Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...

    Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

    Journal for ImmunoTherapy of Cancer 2017 5:79

    Published on: 17 October 2017

  2. Research article

    Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

    Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...

    Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm

    Journal for ImmunoTherapy of Cancer 2017 5:81

    Published on: 17 October 2017

  3. Review

    Immuno-thermal ablations – boosting the anticancer immune response

    The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...

    Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

    Journal for ImmunoTherapy of Cancer 2017 5:78

    Published on: 17 October 2017

  4. Research Article

    Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

    Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases tr...

    Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada and Kathryn Beal

    Journal for ImmunoTherapy of Cancer 2017 5:76

    Published on: 17 October 2017

  5. Research article

    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

    There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...

    Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana and Ulka Vaishampayan

    Journal for ImmunoTherapy of Cancer 2017 5:82

    Published on: 17 October 2017

  6. Erratum

    Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

    Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Journal for ImmunoTherapy of Cancer 2017 5:80

    Published on: 28 September 2017

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:68

  7. Research article

    High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

    Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...

    Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

    Journal for ImmunoTherapy of Cancer 2017 5:74

    Published on: 19 September 2017

  8. Research article

    Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

    Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...

    Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

    Journal for ImmunoTherapy of Cancer 2017 5:72

    Published on: 19 September 2017

  9. Meeting report

    Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

    Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...

    Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

    Journal for ImmunoTherapy of Cancer 2017 5:77

    Published on: 19 September 2017

  10. Research article

    Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

    Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in co...

    Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville

    Journal for ImmunoTherapy of Cancer 2017 5:70

    Published on: 19 September 2017

  11. Research article

    Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

    Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...

    Veronika Kremer, Maarten Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Journal for ImmunoTherapy of Cancer 2017 5:73

    Published on: 19 September 2017

  12. Research article

    Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

    Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in...

    Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher

    Journal for ImmunoTherapy of Cancer 2017 5:71

    Published on: 19 September 2017

  13. Case report

    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

    Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinu...

    Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal and David Jablons

    Journal for ImmunoTherapy of Cancer 2017 5:75

    Published on: 19 September 2017

  14. Research article

    Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer

    Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...

    Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young

    Journal for ImmunoTherapy of Cancer 2017 5:69

    Published on: 15 August 2017

  15. Research article

    Tumor-derived exosomes induce CD8+ T cell suppressors

    The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...

    Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman

    Journal for ImmunoTherapy of Cancer 2017 5:65

    Published on: 15 August 2017

  16. Research article

    Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

    Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...

    Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh

    Journal for ImmunoTherapy of Cancer 2017 5:67

    Published on: 15 August 2017

  17. Research article

    The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

    T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...

    Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson

    Journal for ImmunoTherapy of Cancer 2017 5:63

    Published on: 15 August 2017

  18. Position Article and Guidelines

    Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

    The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and dest...

    Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Journal for ImmunoTherapy of Cancer 2017 5:68

    Published on: 15 August 2017

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:80

  19. Research article

    Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...

    Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

    Journal for ImmunoTherapy of Cancer 2017 5:64

    Published on: 15 August 2017

  20. Case report

    Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

    Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1...

    Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott and Toni K. Choueiri

    Journal for ImmunoTherapy of Cancer 2017 5:66

    Published on: 15 August 2017

  21. Case report

    Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes

    The tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype, that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163. The pr...

    Michael C. Topf, Madalina Tuluc, Larry A. Harshyne and Adam Luginbuhl

    Journal for ImmunoTherapy of Cancer 2017 5:60

    Published on: 18 July 2017

Previous Page Page 1 of 59 Next Page
JITC logo

Advertisement